IRIS
PERA, MARIA CARMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.851
NA - Nord America 1.211
EU - Europa 835
SA - Sud America 741
AF - Africa 194
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.835
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 1.343
US - Stati Uniti d'America 1.140
BR - Brasile 550
VN - Vietnam 484
CN - Cina 413
HK - Hong Kong 272
NL - Olanda 201
IT - Italia 178
FR - Francia 157
ZA - Sudafrica 132
AR - Argentina 74
BD - Bangladesh 59
RU - Federazione Russa 59
DE - Germania 52
IN - India 47
IQ - Iraq 41
AT - Austria 37
IE - Irlanda 35
GB - Regno Unito 34
CO - Colombia 33
MX - Messico 32
EC - Ecuador 24
TR - Turchia 23
PK - Pakistan 22
MA - Marocco 20
CA - Canada 16
JP - Giappone 16
VE - Venezuela 16
PH - Filippine 15
PY - Paraguay 15
SA - Arabia Saudita 14
ID - Indonesia 12
UA - Ucraina 11
UY - Uruguay 11
UZ - Uzbekistan 11
JO - Giordania 10
KE - Kenya 10
KR - Corea 10
TN - Tunisia 10
CL - Cile 9
ES - Italia 9
PL - Polonia 9
LT - Lituania 8
SE - Svezia 8
DZ - Algeria 7
AZ - Azerbaigian 6
BG - Bulgaria 6
IL - Israele 6
JM - Giamaica 6
PE - Perù 6
TH - Thailandia 6
DO - Repubblica Dominicana 5
EG - Egitto 5
NP - Nepal 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
KZ - Kazakistan 4
LB - Libano 4
CH - Svizzera 3
ET - Etiopia 3
GE - Georgia 3
HN - Honduras 3
IR - Iran 3
MY - Malesia 3
PT - Portogallo 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
EE - Estonia 2
FI - Finlandia 2
GR - Grecia 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
RO - Romania 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AO - Angola 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CM - Camerun 1
HU - Ungheria 1
KW - Kuwait 1
LC - Santa Lucia 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 5.833
Salva come PNG Salva come JPEG
Città #
Singapore 601
San Jose 404
Hong Kong 256
Beijing 153
Ho Chi Minh City 151
Hanoi 125
Johannesburg 120
Ashburn 118
Dallas 118
Santa Clara 115
Lauterbourg 96
Groningen 86
São Paulo 43
Los Angeles 40
Moscow 36
Dublin 34
Rio de Janeiro 34
Milan 29
Buffalo 25
Nuremberg 25
Haiphong 21
Munich 17
New York 16
Parma 16
Shanghai 16
Brasília 14
Da Nang 14
Hefei 14
Bologna 13
Council Bluffs 13
Tokyo 13
Vienna 13
Baghdad 12
Biên Hòa 11
Quito 11
Amman 10
San Francisco 10
Ankara 9
Can Tho 9
Columbus 9
Nairobi 9
Ninh Bình 9
Tashkent 9
Frankfurt am Main 8
Guangzhou 8
Hải Dương 8
Warsaw 8
Boston 7
Caracas 7
Curitiba 7
Dhaka 7
New Delhi 7
Tianjin 7
Baku 6
Belo Horizonte 6
Bogotá 6
Brooklyn 6
Chicago 6
London 6
Montevideo 6
Phoenix 6
Thái Nguyên 6
Toronto 6
Amsterdam 5
Aracaju 5
Asunción 5
Boardman 5
Buenos Aires 5
Carpi 5
Casablanca 5
Denver 5
Erbil 5
Forlì 5
Guarulhos 5
Hyderabad 5
Istanbul 5
Jeddah 5
Karachi 5
Karbala 5
Mexico City 5
Montreal 5
Recife 5
Rosario 5
Stockholm 5
Atlanta 4
Brescia 4
Bắc Ninh 4
Campinas 4
Caxias do Sul 4
Conselheiro Lafaiete 4
Dammam 4
Formosa 4
Guayaquil 4
Gustavo Adolfo Madero 4
Houston 4
Kingston 4
Lahore 4
Lima 4
Maldonado 4
Medellín 4
Totale 3.200
Salva come PNG Salva come JPEG
Nome #
Airway Colonization in Children with Medical Complexity: Challenges and Management Strategies 152
Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence 88
Beyond Muscle Weakness: Unraveling Endocrine and Metabolic Dysfunctions in Duchenne Muscular Dystrophy, a Narrative Review 85
Scoliosis in spinal muscular atrophy in the era of disease-modifying therapy: a scoping review 82
An observational study of functional abilities in infants, children, and adults with type 1 SMA 75
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 74
What did we learn from new treatments in SMA? A narrative review 73
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 73
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 72
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 70
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 67
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 67
Risdiplam in Type 1 Spinal Muscular Atrophy 66
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 65
Spinal muscular atrophy — insights and challenges in the treatment era 64
An observational study of functional abilities in infants, children, and adults with type 1 SMA 64
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 63
Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen 63
Longitudinal natural history of type I spinal muscular atrophy: A critical review 63
Assessing floppy infants: a new module 62
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 62
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression 62
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 60
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 60
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 60
Clinical Variability in Spinal Muscular Atrophy Type III 60
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 60
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 59
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 58
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 58
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 58
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data 57
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 57
Early neurodevelopmental assessment in Duchenne muscular dystrophy 57
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 57
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 56
Sleep disorders in spinal muscular atrophy 56
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 56
Early treatment of type II SMA slows rate of progression of scoliosis 56
Developmental milestones in type I spinal muscular atrophy 56
Revised upper limb module for spinal muscular atrophy: Development of a new module 55
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 55
Developmental milestones in type I spinal muscular atrophy 55
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 54
How to Manage Electrical Status Epilepticus in Sleep 54
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 54
Development of an academic disease registry for spinal muscular atrophy 53
Italian validation of the SMA independence scale–upper limb module 53
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 53
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 52
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 52
Old measures and new scores in spinal muscular atrophy patients 52
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 52
Long term follow-up of scoliosis progression in type II SMA patients 52
Neonatal hypotonia and neuromuscular conditions 51
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 51
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 51
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 50
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 50
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 50
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 50
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 50
Predominant distal muscle involvement in spinal muscular atrophy 49
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 49
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 49
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 49
Pregnancy in the Era of Disease-Modifying Therapies for Spinal Muscular Atrophy: Considerations From a Case Report 49
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 48
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 48
Revised upper limb module for spinal muscular atrophy: 12 month changes 48
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 48
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 48
Gain and loss of abilities in type II SMA: A 12-month natural history study 47
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 47
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 47
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 47
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 47
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 47
Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded 47
Traumatic Childbirth Experiences and their Association with Postpartum Psychiatric Disorders: A Systematic Review 47
Two journeys, one diagnosis: exploring the clinical outcomes of twins with congenital myopathy 46
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 45
Epileptic Encephalopathies with Status Epilepticus during Sleep: New Techniques for Understanding Pathophysiology and Therapeutic Options 45
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 45
SFP CO-31 - Inflammatory optic neuritis: Course and prognostic factors in 102 children|SFP CO-31 - Névrites optiques inflammatoires: évolution et facteurs pronostiques chez 102 enfants 45
Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy 45
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 45
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 44
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 44
Treatment of spinal muscular atrophy 44
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 43
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 43
Revised upper limb module for spinal muscular atrophy: Development of a new module 42
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 42
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 42
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 41
MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients 41
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis 41
Sudden and isolated Broca's aphasia: a new clinical phenotype of anti NMDA receptor antibodies encephalitis in children 40
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 40
Totale 5.526
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.355
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.355
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.631 0 0 318 55 85 97 50 55 234 215 111 411
2025/20264.323 325 491 635 479 585 202 552 120 564 370 0 0
Totale 5.954